Equities research analysts at JPMorgan Chase & Co. (NYSE: JPM) boosted their price target on shares of Celsion Co. (NASDAQ: CLSN) to $8.50 in a research note to investors on Thursday.
Separately, analysts at Zacks Investment Research reiterated a “neutral” rating on shares of Celsion Co. in a research note to investors on Thursday, December 30th.
Shares of Celsion Co. traded up 0.54% during mid-day trading on Friday, hitting $3.74. Celsion Co. has a 52 week low of $1.98 and a 52 week high of $4.37. The stock’s 50-day moving average is $3.44 and its 200-day moving average is $2.81. The company has a market cap of $58.6 million.
Celsion Corporation (Celsion) is an oncology drug development company focused on improving treatment for those suffering with aggressive and difficult to treat forms of cancer. Its lead product ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer and a Phase II study for recurrent chest wall breast cancer. ThermoDox is a liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a range of cancers. Localized mild hyperthermia (39.5-42 degrees Celsius) releases the entrapped doxorubicin from the liposome enabling concentrations of doxorubicin to be deposited preferentially in a targeted tumor. The Company is in a Phase III clinical trial for primary liver cancer and a Phase II study for recurrent chest wall breast cancer.